Abstract Topics

  • Immune-Mediated Inflammatory Diseases (IMIDs) with a focus on
    • Rheumatology (RA, IBD, Psoriasis) 
    • Autoinflammation (JIA etc.) 
    • Rare diseases as role models for large IMDs indications  (target identication and target validation)
    • Current status of Precision Medicine in IMDs, case studies 
    • What is the status of prevention, early diagnosis in IMDIs
    • Drug Development status quo
    • Functional food and nutraceuticals
    • The Microbiome in IMIDs
    • How to build holistic next generation customer centric solutions for chronic IMDS?

  • Patient stratification, “Biomarkers”, AI, RWD, data sciences & multi-omics
    • Status of patients stratification, subgroup identification and “biomarkers”
    • AI a hyped buzzword while most data sizes are small in medicine; how to scale algorithms to big data.
    • Machine/Deep Learning models and other concepts for longitudinal multi-omics analysis
    • Validating “black box” analytics
    • Garbage in – garbage out

  • Challenges and Progress in clinical trial design for chronic debilitation IMIDs
    • Next generation clinical trials, N-of-1, longitudinal trials as an emerging paradigm
    • “Virtual” or remote clinical trials, sensors and wearables
    • Real World studies
    • Choose the best end point study that provides answers and that has a high probability of achievement
    • Design studies that provide high quality data and can be used for decision making 
    • Include criteria that enable fast recruitment of patients; Choose design elements and inclusion/exclusion criteria that increase the probability of success for the study